Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time
暂无分享,去创建一个
Martin Schumacher | Monika Engelhardt | Stefanie Hieke | M. Schumacher | M. Engelhardt | Martina Kleber | Christine König | M. Kleber | S. Hieke | C. König | Christine König
[1] Kenneth R Hess,et al. Getting More Out of Survival Data by Using the Hazard Function , 2014, Clinical Cancer Research.
[2] M. Beksac,et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma , 2014, Haematologica.
[3] M. Jung,et al. Vorinostat (V) In Combination With Bortezomib (B), Doxorubicin (D) and Dexamethasone (D) (VBDD) In Patients With Refractory Or Relapsed Multiple Myeloma: An Interim Phase I/II Analysis , 2013 .
[4] Katherine S Panageas,et al. Dynamic prognostication using conditional survival estimates , 2013, Cancer.
[5] B. Pégourié,et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. L. Bergsagel,et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. , 2013, Blood.
[7] L. Bolondi,et al. Conditional Survival after Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients , 2012, Clinical Cancer Research.
[8] H. Putter,et al. Dynamic Prediction in Clinical Survival Analysis , 2011 .
[9] R. Wäsch,et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM–comorbidity score , 2011, Blood cancer journal.
[10] J. Besalduch,et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. , 2011, Blood.
[11] Greg Yothers,et al. Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] K. Aldape,et al. Polymorphisms in the Interleukin-4 Receptor Gene are Associated with Better Survival in Patients with Glioblastoma , 2008, Clinical Cancer Research.
[13] E Graf,et al. Quantifying the Predictive Performance of Prognostic Models for Censored Survival Data with Time‐Dependent Covariates , 2008, Biometrics.
[14] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[15] H. Brenner,et al. Recent major improvement in long-term survival of younger patients with multiple myeloma. , 2008, Blood.
[16] J. Crowley,et al. International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Olsen,et al. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.
[19] S. Salmon,et al. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.
[20] B. O'Sullivan,et al. Prognostic Factors in Cancer , 1995, UICC International Union Against Cancer / Union Internationale Contre le Cancer.
[21] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.